• Article  

      Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group 

      Briassoulis, E. Ch; Pavlidis, Nicholas; Terret, C.; Bauer, J.; Fiedler, W.; Schöffski, P.; Raoul, J. L.; Hess, D.; Selvais, R.; Lacombe, D.; Bachmann, P.; Fumoleau, P. (2003)
      The activity of glufosfamide (β-D-glucopyranosyl-N,N′ -di-(2-chloroethyl)-phosphoric acid diamide) against pancreatic cancer was investigated in a multicentre, phase II clinical study. Chemotherapy-naïve patients with ...
    • Article  

      Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: A European consensus position paper 

      Casali, Paolo G.; Bruzzi, P.; Bogaerts, Jan; Blay, Jean-Yves; Aapro, M. S.; Adamou, A.; Berruti, A.; Bressington, J.; Bruzzi, B.; Capocaccia, R.; Cardoso, Fatima; Celis, J. E.; Cervantes, A.; Ciardiello, F.; Claussen, C.; Coleman, M.; Comis, S.; Craine, S.; Boltz, D. De; Lorenzo, F. De; P, Angelo Dei Tos; Gatta, G.; Geissler, J.; Giuliani, R.; Grande, E.; Gronchi, A.; Jezdic, S.; Jonsson, B.; Jost, Lorenz M.; Keulen, H.; Lacombe, D.; Lamory, G.; Cam, Y. Le; Priolo, S. Leto di; Licitra, Lisa; Macchia, F.; Margulies, A.; Marreaud, S.; McVie, G.; Narbutas, S.; Oliver, K.; Pavlidis, Nicholas; Pelouchova, J.; Pentheroudakis, George; Piccart, M.; Pierotti, M. A.; Pravettoni, G.; Redmond, K.; Riegman, P.; Ruffilli, M. P.; Ryner, D.; Sandrucci, S.; Seymour, M.; Torri, V.; Trama, A.; Belle, S. Van; Vassal, G.; Wartenberg, M.; Watts, C.; Wilson, A.; Yared, W. (2015)
      While they account for one-fifth of new cancer cases, rare cancers are difficult to study. A higher than average degree of uncertainty should be accommodated for clinical as well as for population-based decision making. ...